Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-CHIVA2: Nivolumab after chemotherapy in HIV-positive patients with advanced non-small cell lung cancer
2016-003796-22Phase 2Completed
- Sponsor
- IFCT
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC) and human immunodeficiency virus infection (HIV), sponsored by IFCT. Primary endpoint: Disease control rate. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-003796-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003796-22.